Business Context and Reporting Period
This Form 8-K Current Report was filed by Genprex, Inc. on February 23, 2026. The filing reports on significant intellectual property developments regarding the company's lead oncology drug candidate, REQORSA, and provides updates on the Acclaim-3 clinical trial.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on operational and regulatory milestones rather than financial performance data.
Material Changes and Developments
- Japanese Patent Grant: The Japanese Patent Office issued a favorable Appeal Decision granting a patent for the use of REQORSA in combination with PD-L1 antibodies to treat cancer.
- European Patent Grant: The European Patent Office issued a Decision to Grant a patent for the combination of REQORSA and PD-1 antibodies to treat cancer.
- IP Portfolio Expansion: These grants complement existing patents held in the U.S., Korea, Mexico, Russia, Australia, Chile, China, Singapore, and the EU, solidifying global protection for therapeutic combinations.
Outlook, Management Commentary, and Risks
Clinical Trial Progress (Acclaim-3)
Genprex is conducting the Acclaim-3 Phase 1/2 clinical trial evaluating REQORSA combined with Genentech's Tecentriq (atezolizumab) for extensive stage small cell lung cancer (ES-SCLC). Key details include:
- Status: Phase 1 dose escalation is complete with no dose-limiting toxicities.
- Phase 2 Expansion: Expected to enroll approximately 50 patients.
- Timeline: Enrollment of the first 25 patients for interim analysis is expected in the first half of 2026, with the interim analysis occurring in the second half of 2026.
- Primary Endpoint: 18-week progression-free survival rate from the start of maintenance therapy.
- Regulatory Designations: The trial holds FDA Fast Track and Orphan Drug Designations.
Risks and Forward-Looking Statements
Management cautions that forward-looking statements are subject to significant risks, including:
- Ability to advance clinical development and commercialization according to projected timelines.
- Success of clinical trials and regulatory approvals.
- Financial status, including the ability to maintain Nasdaq listing compliance and continue as a going concern.
- Ability to obtain capital to meet long-term liquidity needs.
- Performance of third-party vendors and manufacturers.
Investor Verification Checklist
- Verify the specific scope and claims of the newly granted Japanese and European patents.
- Monitor the enrollment progress of the Acclaim-3 Phase 2 expansion study against the H1 2026 target for the first 25 patients.
- Review the company's most recent Form 10-K for detailed risk factors regarding liquidity and Nasdaq compliance.
- Confirm the status of the interim analysis scheduled for the second half of 2026.